6. $500 million – Iowa Public Employees’ Retirement System, et al. v. Bank Of America Corp., Case No. 17 Civ. 6221 (S.D.N.Y. Sept. 1, 2023) (preliminary settlement approval granted in a class action to resolve claims that major banks colluded to thwart modernization of the trillion-dollar stock loan market). 7. $385 million – In Re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation , Case No. 13-MD-2445 (E.D. Penn. Oct. 30, 2023) (preliminary settlement approval granted in a class action alleging that the company violated certain state antitrust, consumer protection, and unjust enrichment laws in the United States, harming competition and causing class members to overpay for Suboxone). 8. $246.8 million – In Re HIV Antitrust Litigation, Case No. 19-CV-2563 (N.D. Cal. Sept. 21, 2023) (preliminary settlement approval granted in a class action to resolve claims that the pharmaceutical company colluded with Teva to delay generic versions of HIV medications). 9. $185.9 million – Dennis, et al. v. JPMorgan Chase & Co., Case No. 17 Civ. 6946 (S.D.N.Y. May 25, 2023) (final settlement approval granted for a class action resolving claims brought by a group of investors alleging that banks manipulated the currency benchmark is known as the Australian Bank Bill Swap Reference Rate). 10. $126.8 million – In Re Novartis And Par Antitrust Litigation , Case No. 18 Civ. 4361 (S.D.N.Y. Oct. 12, 2023) (final settlement approval granted for a class action resolving claims brought by a group of direct purchasers accusing the companies of delaying the release of a generic version of the blood pressure drug Exforge).
18
© Duane Morris LLP 2024
Duane Morris Antitrust Class Action Review – 2024
Made with FlippingBook - professional solution for displaying marketing and sales documents online